Jump to content
RemedySpot.com

CDC on mold- 2005

Rate this topic


Guest guest

Recommended Posts

Guest guest

This one statement by NIAD in 1996 says alot:isolated outbreaks of

other fungal diseases in people with normal immune systems have

occurred recently in the United States.

U.S. Department of Health and Human Services

Centers for Disease Control and Prevention

Exposure to Mold

Information for Pregnant and Breastfeeding Women

This sheet talks about the risks that exposure to mold can have

during

pregnancy. With each pregnancy, all women have a 3% to 5% chance of

having a baby

with a birth defect. This information should not take the place of

medical care and

advice from your health care provider.

http://www.otispregnancy.org/pdf/mold.pdf

CASE DEFINITION

Chemical Emergencies

Trichothecene Mycotoxins

Clinical description

March 17, 2005

Trichothecene mycotoxins might be weaponized and dispersed through

the air or mixed in food or beverages. Initially, route-specific

effects are typically prominent. Dermal exposure leads to burning

pain, redness, and blisters, and oral exposure leads to vomiting and

diarrhea. Ocular exposure might result in blurred vision, and

inhalational exposure might cause nasal irritation and cough.

Systemic symptoms can develop with all routes of exposure and might

include weakness, ataxia, hypotension, coagulopathy, and death (1).

This document is based on CDC's best current information. It may be

updated as new information becomes available. For more information,

visit www.bt.cdc.gov/chemical, or call CDC at 800-CDC-INFO (English

and Spanish) or 888-232-6348 (TTY).

Mold Prevention Strategies and Possible Health Effects in the

Aftermath of Hurricanes and Major Floods

June 9, 2006 / 55(RR08);1-27

http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5508a1.htm?

s_cid=rr5508a1_e

How Persons Are Exposed to Mold

Mold exposure can produce disease in several ways. Inhalation is

usually presumed to be the most important mechanism of exposure to

viable (live) or nonviable (dead) fungi, fungal fragments or

components, and other dampness-related microbial agents in indoor

environments. The majority of fungal spores have aerodynamic

diameters of 2--10 µm, which are in the size range that allow

particles to be deposited in the upper and lower respiratory tract

(5). Inhalation exposure to a fungal spore requires that the spore

be initially aerosolized at the site of growth. Aerosolization can

happen in many ways, ranging from disturbance of contaminated

materials by human activity to dispersal of fungi from contaminated

surfaces in heating, ventilating, and air-conditioning (HVAC)

systems. Fungal spores also can be transported indoors from

outdoors. Overall, the process of fungal-spore aerosolization and

related issues (e.g., transport, deposition, resuspension, and

tracking of fungi to other areas) are poorly understood.

Persons can be exposed to mold through skin contact, inhalation, or

ingestion.

Factors That Cause Disease from Mold

Numerous species of mold cause infection through respiratory

exposure. In general, persons who are immunosuppressed are at

increased risk for infection from mold (11). Immunosuppression can

result from immunosuppressive medication, from medical conditions

and diseases that cause immunosuppression, or from therapy for

cancer that causes transient immunosuppression. Although certain

species of mold cause infection (5,8,11), many mold species do not

cause infection. Infections from mold might be localized to a

specific organ or disseminated throughout the body.

Many of the major noninfectious health effects of mold exposure have

an immunologic (i.e., allergic) basis (6). Exposure to mold can

sensitize persons, who then might experience symptoms when re-

exposed to the same mold species. For sensitized persons, hay fever

symptoms and asthma exacerbations are prominent manifestations of

mold allergy (6). Although different mold species might have

different propensities to cause allergy, available data do not

permit a relative ranking of species by risk for creating or

exacerbating allergy. In addition, exposure to beta glucans might

have an inflammatory effect in the respiratory system (12).

Prolonged exposure to high levels of mold (and some bacterial

species) can produce an immune-mediated disease known as

hypersensitivity pneumonitis (13). Clinically, hypersensitivity

pneumonitis is known by the variety of exposures that can cause this

disorder (e.g., farmer's lung, woodworker's lung, and malt worker's

lung).

Population-Specific Recommendations for Protection From Exposure to

Mold in Buildings

CDC 2005 moldtable

Footnotes

1. Significant mold contamination is assumed if the building's

interior was saturated with water for more than 48 hours, extensive

water damage is present, extensive mold growth is visible,

or " mildew " odors are clearly stronger than before Hurricanes

Katrina and Rita.

2. A visible dust cloud suggests high potential for exposure.

However, activities can be associated with high fungal exposure even

without visible dust. Consider more protective interventions for

activities of longer duration or greater frequency.

3. Recommended respiratory protection for residents is a respirator

at least as protective as an N-95 filtering face piece. Respirator

protection for workers in isolated areas of mold contamination (100

square feet or less) or small isolated areas of heating,

ventilation, and air conditioning (HVAC) systems (10 square feet or

less) where mold is disturbed is a respirator at least as protective

as an N-95 filtering face piece. For working in areas of extensive

contamination (greater than 100 contiguous square feet) or HVAC

systems with large areas of contamination (greater than 10 square

feet) and significant mold-containing dust, full face-piece

respirators with N100, R100, P100 particulate filters (or for

powered air-purifying respirators – HEPA filters) are recommended.

Gloves and dermal protection.

4. Occlusive eye protection (safety goggles, not regular

eyeglasses); see discussion of personal protective equipment (PPE)

in Chapter 4 of CDC's report, Mold: Prevention Strategies and

Possible Health Effects in the Aftermath of Hurricanes Katrina and

Rita. Available at: http://www.bt.cdc.gov/disasters/mold/report/.

5. Transplant recipients, including organ or hematopoietic stem cell

recipients within 6 months of transplant or during periods of

substantial immunosuppression; neutropenia (neutrophil count <

500/ & #956;L) due to any cause (including neoplasm, cancer chemotherapy);

CD4+ lymphopenia (lymphocyte count < 200/ & #956;L) due to any cause,

including HIV infection. Affected individuals should consult with

their physicians before entering the affected area.

6. Includes immunosuppressant drug therapy, such as cancer

chemotherapy, corticosteroid, or other immunosuppressive drug

therapy; and diseases impairing host defense such as leukemia or

lymphoma. Affected individuals should consult with their physicians

before entering the affected area. Duration and frequency of

exposures should be minimal.

7. Such diseases include COPD, asthma not exacerbated by mold,

cystic fibrosis, and cavitary tuberculosis. Risk of airway

colonization and subsequent diseases following mold exposure is

unknown. Recommendations are based on best professional judgment.

8. The optimal treatment for allergic rhinitis, allergic asthma, or

hypersensitivity pneumonitis is avoidance of the sensitizing agent.

If symptoms occur despite the recommended preventive measures,

avoidance of exposure is indicated. In many cases, allergic etiology

of rhinitis or asthma needs to be inferred from clinical

information, since the available diagnostic reagents for documenting

IgE-sensitization to fungi are mostly unstandardized. Similarly, the

precise antigenic agent causing hypersensitivity pneumonitis is

often unclear.

9. The level of risk associated with exposure activities and the

potential benefit of recommended PPE are unknown for these

vulnerable populations. Due caution is recommended.

10. Exposure-reducing behavior and respiratory protection

are problems for this group.

Important: See Table on first page.

Centers for Disease Control and Prevention

http://www.bt.cdc.gov/disasters/pdf/flyer-get-rid-of-mold.pdf

by the way, regarding inhaled:

From the Website of the Center for Disease Control:

Mold Toxins (Mycotoxins)

Molds can produce toxic substances called mycotoxins. Some

mycotoxins cling

to the surface of mold spores; others may be found within spores.

More than

200 mycotoxins have been identified from common molds, and many more

remain to

be identified. Some of the molds that are known to produce

mycotoxins are

commonly found in moisture-damaged buildings. Exposure pathways for

mycotoxins

can include inhalation, ingestion, or skin contact. Although some

mycotoxins

are well known to affect humans and have been shown to be

responsible for

human health effects, for many mycotoxins, little information is

available.

Aflatoxin B1 is perhaps the most well known and studied mycotoxin.

It can be

produced by the molds Aspergillus flavus and Aspergillus

parasiticus and is

one of the most potent carcinogens known. Ingestion of aflatoxin B1

can cause

liver cancer. There is also some evidence that inhalation of

aflatoxin B1

can cause lung cancer. Aflatoxin B1 has been found on contaminated

grains,

peanuts, and other human and animal foodstuffs. However,

Aspergillus flavus and

Aspergillus parasiticus are not commonly found on building

materials or in

indoor environments.

Much of the information on the human health effects of inhalation

exposure

to mycotoxins comes from studies done in the workplace and some case

studies

or case reports.* Many symptoms and human health effects attributed

to

inhalation of mycotoxins have been reported including: mucous

membrane irritation, skin rash, nausea, immune system suppression,

acute or chronic liver damage, acute or chronic central nervous

system damage, endocrine effects, and cancer.

More studies are needed to get a clear picture of the health effects

related

to most mycotoxins. However, it is clearly prudent to avoid exposure

to molds and

mycotoxins.

http://www.cdc.gov/ncidod/eid/vol3no2/miller.htm

Synopses

Polycystic Kidney Disease: An Unrecognized Emerging Infectious

Disease?

Marcia A. -Hjelle,* J. Hjelle,* ,*

R. Mayberry,† Ann Dombrink-Kurtzman,‡ W. ,‡

Deborah M. Nowak,* and S. Darras*

*University of Illinois College of Medicine at Peoria, Peoria,

Illinois, USA; †East Tennessee State University, City,

Tennessee, USA; and ‡U.S. Department of Agriculture, Agricultural

Research Service, Peoria, Illinois, USA

Subject: CDC, IOM Damp Indoor Spaces, Mold Associated Illnesses

Summary of Institute of Medicine's Damp Indoor Spaces and Health

Review

(2004)

Evidence of Association

Table 1: Association between Damp Indoor Environments and Mold Health

Outcomes

Health outcome or symptom Exposure to damp indoor environments

Presence of

mold/other agents in damp indoor environments Upper respiratory tract

symptoms_1_ (http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#1)

Sufficient

evidence of an association_7_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#7) Cough_2_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#2)

Sufficient evidence of an association Wheeze_2_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#2) Sufficient

evidence

of an association Asthma

symptoms in sensitized persons with asthma Sufficient evidence of an

association Hypersensitivity pneumonitis_3_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#3) in

susceptible

persons Studied in relation to specific

agents Sufficient evidence of an association Shortness of breath

(dyspnea)_2_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#2) Limited or

suggestive evidence_8_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#8)

Inadequate or insufficient evidence_9_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#9)

Respiratory illness

in otherwise healthy children Limited or

suggestive evidence Respiratory illness in otherwise healthy adults

Inadequate

or insufficient evidence _Acute idiopathic pulmonary hemorrhage in

infants_

(http://www.cdc.gov/nceh/airpollution/mold/AIPHIcasedef.htm)

Inadequate or

insufficient evidence Fungal sinusitis_4_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#4) No

specific studies

associated the condition with damp

or moldy indoor spaces Severe respiratory infections in people whose

immune system is severely immunocompromised_5_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#5) Not

applicable_10_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#10)

Sufficient evidence

of an association

Fungus-related illnesses in people whose immune system is severely

immunocompromised_5_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#5) and who

have

_chronic obstructive pulmonary disease (COPD)_

(http://www.cdc.gov/nceh/airpollution/copd/default.htm) Not

applicable_10_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#10)

Sufficient evidence

of an association Colonization and

potential lung infection in people with some chronic pulmonary

disorders_6_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#6) Not

applicable_10_

(http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#10)

Sufficient evidence

of an association

Notes:

1. Upper respiratory tract symptoms include nasal congestion,

rhinitis,

allergic rhinitis “hay fever " , sneezing, runny or itchy nose,

sinusitis and

sore throat.

2. Lower respiratory tract symptoms include cough with or without

production of phlegm, wheeze, chest tightness, and shortness of

breath.

3. Hypersensitivity pneumonitis is a lung disease that is the result

of

exposure and sensitization to antigens inhaled with a variety of

organic

dusts. Symptoms include dry cough, dyspnea, and fever and sometimes

acute

bronchospasm.

4. Fungal sinusitis is associated with molds but molds may come from

the indoor or the outdoor environment.

5. Immunocompromised persons are at increased risk for fungal

colonization or opportunistic infections.

* It is well established that fungal exposures causes opportunistic

cutaneous and subcutaneous fungal infections of the skin of severely

immunocompromised persons.

* Respiratory infections can result from exposure to fungi, including

Aspergillus spp. and Fusarium spp.

* Severely immunocompromised persons include persons who undergo

high-dose cancer chemotherapy, are recent recipients of a solid-organ

transplant,

or are otherwise immunocompromised.

6. Chronic pulmonary disorders include cystic fibrosis, asthma, and

COPD. Colonization and infections result from exposure to fungi such

as

Aspergillus.

7. " Sufficient evidence of an association " means that studies show an

association between the agent and disease and chance, bias, and

confounding

were ruled out with reasonable confidence.

8. " Limited or suggestive evidence of an association " means that

evidence is suggestive of an association between the agent and the

disease but

is

limited because chance, bias, and confounding cannot be ruled out

with

confidence.

9. " Inadequate or insufficient evidence to determine whether an

association exists " means that the available studies are of

insufficient

quality,

consistency, or statistical power to permit a conclusion regarding

the presence

of an association. Alternatively, no studies exist that examine the

relationship.

10. Respiratory infections, fungus-related illnesses, and

colonization

with lung infection relating to specific organisms.

Source:

Institute of Medicine’s " _Damp Indoor Spaces and Health_

(http://www.nap.edu/books/0309091934/html/) "

(_http://www.nap.edu/books/0309091934/html/_

(http://www.nap.edu/books/0309091934/html/) ).

_top_ (http://www.cdc.gov/nceh/airpollution/mold/iom_sum.htm#top)

____________________________________

_Air Pollution and Respiratory Health_

(http://www.cdc.gov/nceh/airpollution/default.htm) _Environmental

Public

Health Tracking_

(http://www.cdc.gov/nceh/tracking) _Asthma_

(http://www.cdc.gov/asthma/default.htm) _Health

Studies_ (http://www.cdc.gov/nceh/hsb/) _Division of Laboratory

Sciences_

(http://www.cdc.gov/nceh/dls) _Mold_

(http://www.cdc.gov/nceh/airpollution/mold/default.htm) _Emergency

and

Environmental Health Services_

(http://www.cdc.gov/nceh/divisions/eehs.htm) _Radiation Studies_

(http://www.cdc.gov/nceh/radiation/default.htm)

_U.S.-Mexico Border Environmental

Health_ (http://www.cdc.gov/nceh/hsb/borders.htm) _Environmental

Hazards and Health Effects_

(http://www.cdc.gov/nceh/ehhe/default.htm)

_NCEH Home_ (http://www.cdc.gov/nceh/) | _Programs_

(http://www.cdc.gov/nceh/programs.htm) | _Publications_

(http://www.cdc.gov/nceh/publications.htm) |

_Contact Us_ (http://www.cdc.gov/nceh/Information/contact.htm) |

_Privacy_

(http://www.cdc.gov/nceh/privacy/privacy.htm) | _About NCEH_

(http://www.cdc.gov/nceh/Information/about.htm) _

CDC Home_ (http://www.cdc.gov/) | _CDC Search_

(http://www.cdc.gov/search.htm) | _Health Topics A-Z_

(http://www.cdc.gov/health/diseases.htm)

This page last reviewed March 03, 2005

Air Pollution and Respiratory Health Branch

National Center for Environmental Health

Centers for Disease Control and Prevention

http://www.niaid.nih.gov/publications/dateline/0996/page11.htm

NIAID Semptember 1996

------------

New Fact Sheets on Emerging Fungal Diseases

Although still outnumbered by their bacterial and viral

counterparts, fungal pathogens are responsible for an increasing

number of emerging infectious diseases. They account for a growing

proportion of nosocomial, or hospital-acquired, infections,

particularly among organ transplant recipients and other patients

receiving immunosuppressive treatments. Fungal diseases also have

become common among AIDS patients. In addition, isolated outbreaks

of other fungal diseases in people with normal immune systems have

occurred recently in the United States.

NIAID plays a vital role in the effort to reverse the recent inroads

made by these diseases, and supports an increasing number of studies

to improve the prevention, diagnosis, and treatment of fungal

diseases, also known as mycoses. Between 1985 and 1995, the number

of fungal disease research grants and contracts supported by the

Institute increased from 42 to 95. Over the same period, NIAID

funding for mycoses research rose more than fourfold, from $6.5

million to slightly less than $29 million.

--by Bowersox

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...